TY - JOUR
T1 - Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis
AU - Geraldino-Pardilla, Laura
AU - Russo, Cesare
AU - Sokolove, Jeremy
AU - Robinson, William H.
AU - Zartoshti, Afshin
AU - Van Eyk, Jenny V.
AU - Fert-Bober, Justyna
AU - Lima, Joao
AU - Giles, Jon T.
AU - Bathon, Joan M.
N1 - Publisher Copyright:
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Objective. High levels of ACPAs in RA are associated with more severe arthritis and worse prognosis. However, the role of ACPAs in mediating the increased risk of heart failure in RA remains undefined. We examined whether specific ACPAs were associated with subclinical left ventricular (LV) phenotypes that presage heart failure. Methods. Sera from RA patients without clinical cardiovascular disease were assayed for specific ACPAs using a custom Bio-Plex bead assay, and their cross-sectional associations with cardiac magnetic resonance- derived LV measures were evaluated. High ACPA level was defined as ≥ 75th percentile. Findings were assessed in a second independent RA cohort with an expanded panel of ACPAs and LV measures assessed by 3D-echocardiography. Results. In cohort 1 (n = 76), higher levels of anti-citrullinated fibrinogen41-60 and anti-citrullinated vimentin antibodies were associated with a 10 and 6% higher adjusted mean LV mass index (LVMI), respectively, compared with lower antibody levels (P<0.05). In contrast, higher levels of anticitrullinated biglycan247-266 were associated with a 13% lower adjusted mean LVMI compared with lower levels (P<0.001). In cohort 2 (n = 74), the association between ACPAs targeting citrullinated fibrinogen and citrullinated vimentin peptides or protein and LVMI was confirmed: higher anticitrullinated fibrinogen556-575 and anti-citrullinated vimentin58-77 antibody levels were associated with a higher adjusted mean LVMI (19 and 15%, respectively; P<0.05), but no association with biglycan was found. Conclusion. Higher levels of antibodies targeting citrullinated fibrinogen and vimentin peptides or protein were associated with a higher mean LVMI in both RA cohorts, potentially implicating autoimmune targeting of citrullinated proteins in myocardial remodelling in RA.
AB - Objective. High levels of ACPAs in RA are associated with more severe arthritis and worse prognosis. However, the role of ACPAs in mediating the increased risk of heart failure in RA remains undefined. We examined whether specific ACPAs were associated with subclinical left ventricular (LV) phenotypes that presage heart failure. Methods. Sera from RA patients without clinical cardiovascular disease were assayed for specific ACPAs using a custom Bio-Plex bead assay, and their cross-sectional associations with cardiac magnetic resonance- derived LV measures were evaluated. High ACPA level was defined as ≥ 75th percentile. Findings were assessed in a second independent RA cohort with an expanded panel of ACPAs and LV measures assessed by 3D-echocardiography. Results. In cohort 1 (n = 76), higher levels of anti-citrullinated fibrinogen41-60 and anti-citrullinated vimentin antibodies were associated with a 10 and 6% higher adjusted mean LV mass index (LVMI), respectively, compared with lower antibody levels (P<0.05). In contrast, higher levels of anticitrullinated biglycan247-266 were associated with a 13% lower adjusted mean LVMI compared with lower levels (P<0.001). In cohort 2 (n = 74), the association between ACPAs targeting citrullinated fibrinogen and citrullinated vimentin peptides or protein and LVMI was confirmed: higher anticitrullinated fibrinogen556-575 and anti-citrullinated vimentin58-77 antibody levels were associated with a higher adjusted mean LVMI (19 and 15%, respectively; P<0.05), but no association with biglycan was found. Conclusion. Higher levels of antibodies targeting citrullinated fibrinogen and vimentin peptides or protein were associated with a higher mean LVMI in both RA cohorts, potentially implicating autoimmune targeting of citrullinated proteins in myocardial remodelling in RA.
KW - Anti-citrullinated peptide antibody (ACPA)
KW - CVD
KW - RA
KW - Ventricular mass
UR - http://www.scopus.com/inward/record.url?scp=85017276374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017276374&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/kew436
DO - 10.1093/rheumatology/kew436
M3 - Article
C2 - 27994093
AN - SCOPUS:85017276374
SN - 1462-0324
VL - 56
SP - 534
EP - 540
JO - Rheumatology (United Kingdom)
JF - Rheumatology (United Kingdom)
IS - 4
M1 - kew436
ER -